Designed to fit a wearable garment similar to a sports bra, First Warning anticipates bringing their technology to market for an affordable price that will make it widely accessible to all markets.
To learn more, visit http://www.firstwarningsystems.com
About First Warning Systems Process
Temperature readings of breast tissue create a dynamic cell chaos profile using dynamic data which is correlated to dysfunctional circadian genes. Multiple bioinformatics algorithms compare the circadian gene protein profiles to identify breast tissue abnormalities at different stages of development of disturbed breast tissue cells. FWS delivers an objective Clinical Decision Support Service report to the primary care physician with industry leading accuracy.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, NV. FWS’s principal shareholder is Lifeline Biotechnologies, Inc (OTC Market: LLBO). FWS holds the exclusive development, manufacturing and marketing worldwide license from Lifeline, to commercialize the intellectual property. The FWS product line is a device and process that detects breast tissue abnormalities leading to health risk assessment and management and potentially, breast cancer. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets. See FWS’ video, “Breast Cancer Tumor Progression”
Copyright©2012 Vocus, Inc.
All rights reserved